Sell MBX-2982

Description

MBX****2 is a potential first-in-class treatment for type 2 diabetes that targets G protein-coupled receptor **9 (GPR**9), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that MBX****2 is a potent selective orally-active GPR**9 agonist that functions through a unique dual mechanism of action. First, it acts directly on the beta cell to increase insulin secretion. In addition, MBX****2 stimulates release of the incretin GLP*1 from the gut. This dual action is unique and may offer improved glucose homeostasis over existing diabetes therapies, with potential for weight loss and improved islet health.